{"id":"https://openalex.org/W2591966463","doi":"https://doi.org/10.1021/acs.jmedchem.7b00124","title":"Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)","display_name":"Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)","publication_year":2017,"publication_date":"2017-03-03","ids":{"openalex":"https://openalex.org/W2591966463","doi":"https://doi.org/10.1021/acs.jmedchem.7b00124","mag":"2591966463","pmid":"https://pubmed.ncbi.nlm.nih.gov/28257199"},"language":"en","primary_location":{"id":"doi:10.1021/acs.jmedchem.7b00124","doi":"https://doi.org/10.1021/acs.jmedchem.7b00124","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.7b00124","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047829660","display_name":"Ariamala Gopalsamy","orcid":"https://orcid.org/0000-0003-3704-3891","observed_orcids":["https://orcid.org/0000-0003-3704-3891"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ariamala Gopalsamy","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":"https://orcid.org/0000-0003-3704-3891","affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059273534","display_name":"Arjun Narayanan","orcid":"https://orcid.org/0000-0002-3371-4419","observed_orcids":["https://orcid.org/0000-0002-3371-4419"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arjun Narayanan","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013022553","display_name":"Shenping Liu","orcid":"https://orcid.org/0000-0001-9400-3007","observed_orcids":["https://orcid.org/0000-0001-9400-3007"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shenping Liu","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026260331","display_name":"Mihir D. Parikh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mihir D. Parikh","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059751010","display_name":"Robert E. Kyne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert E. Kyne","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037325947","display_name":"Olugbeminiyi Fadeyi","orcid":"https://orcid.org/0000-0002-5525-1304","observed_orcids":["https://orcid.org/0000-0002-5525-1304"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olugbeminiyi Fadeyi","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000903316","display_name":"Michael A. Tones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Tones","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112233133","display_name":"Jonathan J. Cherry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan J. Cherry","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051233243","display_name":"Joseph F. Nabhan","orcid":"https://orcid.org/0000-0002-9600-2347","observed_orcids":["https://orcid.org/0000-0002-9600-2347"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph F. Nabhan","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109097562","display_name":"Gregory J. LaRosa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory LaRosa","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053370712","display_name":"Donna N. Petersen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donna N. Petersen","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063182142","display_name":"Carol A. Menard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carol Menard","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082178342","display_name":"Timothy L. Foley","orcid":"https://orcid.org/0000-0002-5987-5253","observed_orcids":["https://orcid.org/0000-0002-5987-5253"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy L. Foley","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058252388","display_name":"Stephen Noell","orcid":"https://orcid.org/0000-0003-3054-2575","observed_orcids":["https://orcid.org/0000-0003-3054-2575"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Noell","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100989816","display_name":"Yong Ren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yong Ren","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011949689","display_name":"Paula M. Loria","orcid":"https://orcid.org/0000-0003-4690-5991","observed_orcids":["https://orcid.org/0000-0003-4690-5991"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paula M. Loria","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084214334","display_name":"Jodi Maglich-Goodwin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jodi Maglich-Goodwin","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112394485","display_name":"Haojing Rong","orcid":"https://orcid.org/0009-0008-8950-0664","observed_orcids":["https://orcid.org/0009-0008-8950-0664"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haojing Rong","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000265622","display_name":"Lyn H. Jones","orcid":"https://orcid.org/0000-0002-8388-5865","observed_orcids":["https://orcid.org/0000-0002-8388-5865"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lyn H. Jones","raw_affiliation_strings":["Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States"],"raw_orcid":"https://orcid.org/0000-0002-8388-5865","affiliations":[{"raw_affiliation_string":"Medicine\rDesign and \u2021Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Medicine Design and \u2020Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5047829660"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":2.3565,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.88341044,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"60","issue":"7","first_page":"3094","last_page":"3108"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12400","display_name":"Neurogenetic and Muscular Disorders Research","score":0.948199987411499,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12400","display_name":"Neurogenetic and Muscular Disorders Research","score":0.948199987411499,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.016699999570846558,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/spinal-muscular-atrophy","display_name":"spinal muscular atrophy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/2-4-diaminoquinazolines","display_name":"2,4-diaminoquinazolines","score":0.8970000147819519},{"id":"https://openalex.org/keywords/lysosomal-accumulation","display_name":"lysosomal accumulation","score":0.7250000238418579},{"id":"https://openalex.org/keywords/mouse-model","display_name":"mouse model","score":0.3100000023841858},{"id":"https://openalex.org/keywords/physicochemical-properties-of-drugs","display_name":"physicochemical properties of drugs","score":0.5249999761581421}],"concepts":[{"id":"https://openalex.org/C161921814","wikidata":"https://www.wikidata.org/wiki/Q493743","display_name":"SMA*","level":2,"score":0.8104234933853149},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7765378952026367},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7490760684013367},{"id":"https://openalex.org/C2778558090","wikidata":"https://www.wikidata.org/wiki/Q580290","display_name":"Spinal muscular atrophy","level":3,"score":0.6551968455314636},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.6183279156684875},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4557468891143799},{"id":"https://openalex.org/C56783068","wikidata":"https://www.wikidata.org/wiki/Q172867","display_name":"Scavenger","level":3,"score":0.4383944571018219},{"id":"https://openalex.org/C2777752112","wikidata":"https://www.wikidata.org/wiki/Q903238","display_name":"Lead compound","level":3,"score":0.4267379641532898},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.41252970695495605},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4022268056869507},{"id":"https://openalex.org/C2778004101","wikidata":"https://www.wikidata.org/wiki/Q133948","display_name":"Antioxidant","level":2,"score":0.12511911988258362},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.10125800967216492},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08691766858100891},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C114614502","wikidata":"https://www.wikidata.org/wiki/Q76592","display_name":"Combinatorics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004722","descriptor_name":"Endoribonucleases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D004722","descriptor_name":"Endoribonucleases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D004722","descriptor_name":"Endoribonucleases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009134","descriptor_name":"Muscular Atrophy, Spinal","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009134","descriptor_name":"Muscular Atrophy, Spinal","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D009134","descriptor_name":"Muscular Atrophy, Spinal","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055540","descriptor_name":"Survival of Motor Neuron 2 Protein","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057809","descriptor_name":"HEK293 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D062105","descriptor_name":"Molecular Docking Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/acs.jmedchem.7b00124","doi":"https://doi.org/10.1021/acs.jmedchem.7b00124","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.7b00124","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:28257199","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28257199","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8199999928474426}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W1490596873","https://openalex.org/W1879343101","https://openalex.org/W1971358895","https://openalex.org/W1975947882","https://openalex.org/W1977672277","https://openalex.org/W2008834682","https://openalex.org/W2010818290","https://openalex.org/W2012065284","https://openalex.org/W2025718938","https://openalex.org/W2033377350","https://openalex.org/W2052097013","https://openalex.org/W2075181140","https://openalex.org/W2085954882","https://openalex.org/W2089986114","https://openalex.org/W2117528919","https://openalex.org/W2125006413","https://openalex.org/W2134425204","https://openalex.org/W2135399845","https://openalex.org/W2144182419","https://openalex.org/W2153726984","https://openalex.org/W2157606769","https://openalex.org/W2158079842","https://openalex.org/W2159000797","https://openalex.org/W2164938085","https://openalex.org/W2316575052","https://openalex.org/W2395106629","https://openalex.org/W2493190530","https://openalex.org/W2513799405","https://openalex.org/W2757328518"],"related_works":["https://openalex.org/W2757328518","https://openalex.org/W2008834682","https://openalex.org/W2153726984","https://openalex.org/W2117528919","https://openalex.org/W2528298019","https://openalex.org/W7070458461","https://openalex.org/W1971358895","https://openalex.org/W2033377350","https://openalex.org/W1982632616","https://openalex.org/W2444002901"],"abstract_inverted_index":{"The":[0],"C-5":[1],"substituted":[2],"2,4-diaminoquinazoline":[3],"RG3039":[4],"(compound":[5,139],"1),":[6],"a":[7,10,30,40,65],"member":[8],"of":[9,33,43,96,124,137,142],"chemical":[11],"series":[12],"that":[13,69],"was":[14],"identified":[15],"and":[16,25,119],"optimized":[17],"using":[18],"an":[19],"SMN2":[20],"promoter":[21],"screen,":[22],"prolongs":[23],"survival":[24],"improves":[26],"motor":[27],"function":[28],"in":[29,74,80,120,131,149],"mouse":[31,133,151],"model":[32],"spinal":[34],"muscular":[35],"atrophy":[36],"(SMA).":[37],"It":[38],"is":[39,60,64,70,83],"potent":[41],"inhibitor":[42],"the":[44,51,79,93,97,116,130,143],"mRNA":[45],"decapping":[46],"scavenger":[47],"enzyme":[48],"(DcpS),":[49],"but":[50],"mechanism":[52],"whereby":[53],"DcpS":[54,86,107,126],"inhibition":[55,87],"leads":[56],"to":[57,72,85,105,146],"therapeutic":[58],"benefit":[59],"unclear.":[61],"Compound":[62],"1":[63],"dibasic":[66],"lipophilic":[67],"molecule":[68],"predicted":[71],"accumulate":[73],"lysosomes.":[75],"To":[76],"understand":[77],"if":[78],"vivo":[81,132],"efficacy":[82],"due":[84],"or":[88],"other":[89],"effects":[90],"resulting":[91],"from":[92],"physicochemical":[94,111],"properties":[95],"chemotype,":[98],"we":[99,114],"undertook":[100],"structure":[101],"based":[102],"molecular":[103],"design":[104],"identify":[106],"inhibitors":[108,127],"with":[109,129],"improved":[110],"properties.":[112],"Herein":[113],"describe":[115],"design,":[117],"synthesis,":[118],"vitro":[121],"pharmacological":[122],"characterization":[123],"these":[125],"along":[128],"CNS":[134],"PK":[135],"profile":[136],"PF-DcpSi":[138],"24),":[140],"one":[141],"analogs":[144],"found":[145],"be":[147],"efficacious":[148],"SMA":[150],"model.":[152]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-03-16T00:00:00"}